share_log

Goldman Sachs Initiates Protagonist Therapeutics(PTGX.US) With Hold Rating, Announces Target Price $47

Futu News ·  Dec 6 06:31  · Ratings

Goldman Sachs analyst Richard Law CFA initiates coverage on $Protagonist Therapeutics (PTGX.US)$ with a hold rating, and sets the target price at $47.

According to TipRanks data, the analyst has a success rate of 33.3% and a total average return of 6.1% over the past year.

AnalystRecentRatingAutoNews_212032_20241205_4d93cb1864dc9baaf2c6f491490ef612c6f82219_1733466624371882_nn_en

Furthermore, according to the comprehensive report, the opinions of $Protagonist Therapeutics (PTGX.US)$'s main analysts recently are as follows:

  • Protagonist Therapeutics has potential for commercial success with its Phase 3 assets, although they are considered to provide 'limited' financial and mergers and acquisitions upside since they have already been licensed. The significant increase, over 400%, in the stock price of Protagonist over the past two years has been influenced by development progression and licensing agreements, reflecting the current market expectations from both assets.

  • Protagonist Therapeutics is utilizing its peptide technology platform to tackle disorders in hematology and immunology. The expectation is that the share price will rise as clinical risks are mitigated within its pipeline over the coming year, bolstered by multiple catalysts for rusfertide and JNJ-2113. Protagonist is positioned to offer oral alternatives in major blockbuster categories, which are presently overwhelmed by injectable solutions.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment